That's my read on things also. The commentary around the FDA and to a lesser extent EMA is par for the course at this phase of a biotech stock like Invex. IMO the thesis is intact and the risk benefit analysis is in favour of the green side for longer term holders. Plenty to like here but expect some sideways and down action in the month to come. These swings may be a pittance in the future. IMO only.
Ann: Quarterly Report and Appendix 4C, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
